Literature DB >> 2857482

Kinetics of the steroidogenic response to single versus repeated doses of human chorionic gonadotropin in boys in prepuberty and early puberty.

L Dunkel, J Perheentupa, D Apter.   

Abstract

There is accumulating evidence that in adult men excessive amounts of gonadotropins induce testicular desensitization to further gonadotropin stimulus. We evaluated the effects of endogenous gonadotropins and of repeated doses of exogenous human chorionic gonadotropin (hCG) on steroidogenesis by studying prepubertal and pubertal boys. The boys received either two intramuscular injections of hCG 4 days apart (protocol I) or four injections at 3- to 4-day-intervals (protocol II). In protocol I, serum testosterone, 17 alpha-hydroxyprogesterone, and estradiol were measured basally and for 6 days after the second injection, and in protocol II, before each injection and 4 days after the last injection. In the prepubertal-boys, serum testosterone increased from very low basal levels to 10.3 (protocol I) and 8.3 nmol/liter (protocol II). In protocol I the increase after the first injection was 64-fold and in protocol II there was an increase after each injection to a final level 144-fold of the basal. No significant changes were seen in the estradiol levels. In the pubertal boys at genital stage G2, the serum testosterone levels increased after the first two injections, but at genital stage G3, the levels increased only after the first injection. Maximal testosterone increases were 27- and 8-fold, respectively. In pubertal boys estradiol levels increased progressively throughout the stimulation. The major testosterone response ws seen after the first dose of hCG and repeated doses, at least in the pubertal boys, increased estradiol but not testosterone levels, thus causing an estrogen-mediated 17,20-lyase block. We therefore suggest that a single-dose hCG test deserves further evaluation for diagnostic use.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857482     DOI: 10.1203/00006450-198501000-00001

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  7 in total

1.  Effects of oral phosphocysteamine and rectal cysteamine in cystinosis.

Authors:  W G van't Hoff; T Baker; R N Dalton; L C Duke; S P Smith; C Chantler; G B Haycock
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

2.  Effect of hCG or hCG+ treatments in young thalassemic patients with hypogonadotropic hypogonadism.

Authors:  R Balducci; V Toscano; G Finocchi; G Municchi; A Mangiantini; B Boscherini
Journal:  J Endocrinol Invest       Date:  1990-01       Impact factor: 4.256

3.  Germ cell apoptosis after treatment of cryptorchidism with human chorionic gonadotropin is associated with impaired reproductive function in the adult.

Authors:  L Dunkel; S Taskinen; O Hovatta; J L Tilly; S Wikström
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

4.  Evaluation of human chorionic gonadotropin stimulation tests in prepubertal and early pubertal boys.

Authors:  A Kauschansky; M Frydman; M Nussinovitch; I Varsano
Journal:  Eur J Pediatr       Date:  1995-11       Impact factor: 3.183

5.  Pregnancy in phenylketonuria: dietary treatment aimed at normalising maternal plasma phenylalanine concentration.

Authors:  G N Thompson; D E Francis; D M Kirby; R Compton
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

Review 6.  Male hypogonadism.

Authors:  Andrea M Isidori; Elisa Giannetta; Andrea Lenzi
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

7.  The effect of human chorionic gonadotropin treatment on recipient mouse germ cell proliferation following spermatogonial stem cell transplantation of neonatal donor mice.

Authors:  Mohammad Mehdi Akhondi; Reza Akbarzadeh Najar; Mahmood Jeddi-Tehrani; Mohammad-Reza Sadeghi; Amir Hassan Zarnani; Hodjattallah Rabbani; Sheida Salehkhou; Leila Eini; Fatemeh Hoseinzadeh; Mahnaz Heidari
Journal:  Avicenna J Med Biotechnol       Date:  2010-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.